Medical/Pharmaceuticals
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated byHarbour BioMed (HKEX: 02142), announced that it completed seed financing to advance its leading programs, novel antibody therapies to treat congenital adrenal hype...
2023-01-26 09:22
3851
ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies
NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative treatment industry has shown tremendous potential in clinical practices in recent years worldwide,China's blue ocean market welcomes the first wave of acquisitions. ReLive Biotechnologies, Ltd. ("ReLive" or ...
2023-01-26 08:11
2998
Singleron launches single cell eQTL analysis as part of their sequencing service
A new bioinformatic pipeline to investigate single cell eQTL analysis is now
offered in the sequencing service from Singleron Biotechnologies.
COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at
Singleron Biotechnologies
2023-01-25 19:00
2639
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK, Jan. 20, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company mush complete its initial business combination fromJanuary 19, 2023 to February 19, 2023, for each public share that...
2023-01-21 05:33
7098
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thata poster presentation highlighting the Phase 1 preliminary result...
2023-01-20 21:50
5464
International Symposium at the Vatican on Hansen's Disease To Focus on Theme of "Leave No One Behind"
TOKYO, Jan. 20, 2023 /PRNewswire/ -- French Raoul Follereau Fondation, Italian Association Amici di Raoul Follereau and Sasakawa Leprosy (Hansen's Disease) Initiative, in collaboration with the Dicastery for Promoting Integral Human Development, will co-host the "International Symposium at the Va...
2023-01-20 21:00
4690
SK bioscience Appoints New Executives to Accelerate New Growth Strategies
* Two biopharmaceutical experts join SK bioscience to strengthen the future strategies * With recruitment of global talent and capabilities accumulated during the COVID-19 pandemic, SK bioscience will continue to achieve sustainable growth SEOUL, South Korea, Jan. 20, 2023 /PRNewswire/ -- SK ...
2023-01-20 20:00
4023
DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced that the U.S. Food...
2023-01-20 18:00
4174
BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS
TORONTO, Canada and BEIJING, Jan. 20, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at theAmerican Association for Cancer Research (AACR) <...
2023-01-20 13:10
2854
$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases
SAN DIEGO, Jan. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. ("Disc") about 9MW3011 (R&D code in t...
2023-01-20 09:50
3222
NEW THERAPY TO TREAT RARE GASTROINTESTINAL STROMAL TUMOUR APPROVED FOR NEW ZEALAND PATIENTS
* QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ * QINLOCK now being considered by PHARMAC for reimbursement * Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND, New Zealand, Jan. 19, 2023 /PR...
2023-01-20 02:00
3197
Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH
SHANGHAI, Jan. 19, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today reported positive top-line results from the Phase 2a RISE clinical trial of HPG1860, a next gene...
2023-01-19 23:00
3196
Zhongchao Inc. Launches Medication Management Assistance Mini Program to Facilitate Cancer Treatment
SHANGHAI, Jan. 19, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that Zhongxin Medical Technology Co., Ltd. ("Zhongxin"), one of ...
2023-01-19 20:30
3149
Tigermed Completes Acquisition of Marti Farm
HANGZHOU, China and ZAGREB, Croatia, Jan. 19, 2023 /PRNewswire/ -- Tigermed (300347.SZ/3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, announced today the completion of its acquisition of Marti F...
2023-01-19 14:59
5631
China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List
SUZHOU, China, and ROCKVILLE, MD, Jan. 18, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today an...
2023-01-19 11:45
3048
Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023
* Lunit to present two abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict treatment outcomes in liver and colon cancer SEOUL, South Korea, Jan. 18,...
2023-01-18 21:00
2706
Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM
CHENGDU, China, Jan. 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug candidate, for advanced solid tumors will be presented as...
2023-01-18 09:52
2824
IASO Bio Raises Nearly $75 Million in Series C1 Funding
Approaches Commercialization of First Product NANJING and SHANGHAI, China and SAN JOSE, Calif., Jan. 17, 2023 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody p...
2023-01-18 08:00
3207
Asieris Appoints Dr. Linda Wu as Chief Development Officer
SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced thatLinda Wu, Ph.D. will join Asieris...
2023-01-18 07:00
2979
Tanso Biosciences Expands Its Line-up with 250 Mouse GPCRs
TOKYO, Jan. 17, 2023 /PRNewswire/ -- Tanso Biosciences, a leading provider of functional assays for G-protein-coupled receptors (GPCRs), is thrilled to announce a major expansion of its assay platform. Building upon its already extensive coverage of 300 human GPCRs, Tanso Biosciences has added 25...
2023-01-18 00:00
2562
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
A Taste of Thailand: Discover the Spirit of the Elephant at Chang Thai
[Picked up by 282 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Most Read
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
2026-09-03 23:53
9443
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
7279
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
6491
